Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials.

Saved in:
Bibliographic Details
Title: Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials.
Authors: Mayer-Hamblett N; Seattle Children's Research Institute, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA; Department of Biostatistics, University of Washington, Seattle, WA, USA. Electronic address: nicole.hamblett@seattlechildrens.org., Kerper NR; Cystic Fibrosis Foundation, Bethesda, MD, USA., Clancy JP; Cystic Fibrosis Foundation, Bethesda, MD, USA., Davies JC; National Heart and Lung Institute, Imperial College London, London, UK; Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK., Taylor-Cousar JL; Departments of Internal Medicine and Pediatrics, National Jewish Health, Denver, CO, USA., Donaldson SH; Division of Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Bell SC; Department of Respiratory Medicine, Gold Coast University Hospital, Southport, QLD, Australia; School of Medicine and Dentistry, Health Group, Griffith University, Southport, QLD, Australia., Jain R; Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA., Simmonds NJ; National Heart and Lung Institute, Imperial College London, London, UK; Adult Cystic Fibrosis Centre, Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK., Mall MA; Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Centre for Lung Research (DZL), Berlin, Germany; German Center for Child and Adolescent Health (DZKJ), Berlin, Germany., Goss CH; Seattle Children's Research Institute, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA, USA., Rayment JH; Division of Respiratory Medicine, BC Children's Hospital, Vancouver, BC, Canada; Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada., Setiawan L; Seattle Children's Research Institute, Seattle, WA, USA., Pilewski JM; Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Source: The Lancet. Respiratory medicine [Lancet Respir Med] 2025 Dec; Vol. 13 (12), pp. 1108-1118. Date of Electronic Publication: 2025 Jul 30.
Publication Type: Journal Article; Review
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101605555 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2619 (Electronic) Linking ISSN: 22132600 NLM ISO Abbreviation: Lancet Respir Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2213-2619
DOI:10.1016/S2213-2600(25)00206-1